59. A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.
作者: Ikechukwu Adigweme.;Mohammed Yisa.;Michael Ooko.;Edem Akpalu.;Andrew Bruce.;Simon Donkor.;Lamin B Jarju.;Baba Danso.;Anthony Mendy.;David Jeffries.;Anne Segonds-Pichon.;Abdoulie Njie.;Stephen Crooke.;Elina El-Badry.;Hilary Johnstone.;Michael Royals.;James L Goodson.;Mark R Prausnitz.;Devin V McAllister.;Paul A Rota.;Sebastien Henry.;Ed Clarke.
来源: Lancet. 2024年403卷10439期1879-1892页
Microneedle patches (MNPs) have been ranked as the highest global priority innovation for overcoming immunisation barriers in low-income and middle-income countries. This trial aimed to provide the first data on the tolerability, safety, and immunogenicity of a measles and rubella vaccine (MRV)-MNP in children.
|